Parasympathetic nerve activator and parasympathetic nerve activating composition

Abstract

Provided is a parasympathetic nerve activator comprising a compound represented by structural formula (1).

Description

Technical Field

[0001] The present invention relates to a parasympathetic nerve activator and a composition for activating the parasympathetic nerve. Background Art

[0002] Stress has become a big problem in recent years. External stimulation of the body and mind is called stress response. There are physical stress responses such as weather, temperature changes, noise, chemical stress responses such as drugs and harmful chemicals, psychological and social stress responses such as interpersonal relationships, work problems, and family problems.

[0003] In order to keep the internal environment constant in response to external stimuli, organisms have a system called the autonomic nervous system, which includes the sympathetic and parasympathetic nerves.

[0004] The parasympathetic nerves are stimulated when the body is relaxed, such as when eating or sleeping, and play a role in lowering heart rate, dilating blood vessels, activating gastrointestinal function, etc. By activating the parasympathetic nerves, it can be expected that the tension of the sympathetic nerves will be relieved or calmed.

[0005] Thyme, a herb native to the Mediterranean coast of southern Europe, has been reported as a component that activates parasympathetic nerves (for example, see Patent Document 1).

[0006] However, there is still a strong demand for new raw materials that have a parasympathetic nerve activation effect and are highly safe and can be widely used as ingredients for foods, beverages, pharmaceuticals, research reagents, etc., and the current situation is that there is a demand for rapid development.

[0007] In addition, the name of the compound represented by the following structural formula (1) is 3-(4-hydroxy-3-methoxyphenyl) propionic acid (English name: 3-(4-Hydroxy-3-methoxyphenyl)propionic acid). It is known that the compound represented by the following structural formula (1) is detected when a certain type of lactic acid bacteria is cultured using a culture medium containing specific components (for example, refer to Patent Document 2).

[0008] [Chemistry 1]

[0009]

[0010] The compound represented by the structural formula (1) is an effective ingredient of a dipeptidyl peptidase IV activity inhibitor and is known to be a very useful ingredient that can be added to foods and beverages for inhibiting dipeptidyl peptidase IV activity (for example, see Patent Document 3).

[0011] However, it is not known that the compound represented by the above structural formula (1) has a parasympathetic nerve activating effect.

[0012] Prior art literature

[0013] Patent Literature

[0014] Patent Document 1: Japanese Patent Application Publication No. 2022-007470

[0015] Patent Document 2: Japanese Patent Application Publication No. 2014-003929

[0016] Patent Document 3: Japanese Patent Application Publication No. 2020-055887 Summary of the invention

[0017] Problem that the invention aims to solve

[0018] The present invention aims to solve the above-mentioned various conventional problems and achieve the following objectives: Specifically, the present invention aims to provide a parasympathetic nerve activator and a parasympathetic nerve activating composition having excellent parasympathetic nerve activating action and high safety.

[0019] Methods used to solve problems

[0020] The present inventors have conducted intensive studies to solve the above problems and have found that the compound represented by the following structural formula (1) has an excellent parasympathetic nerve activating effect and is highly safe and is useful for parasympathetic nerve activating applications.

[0021] [Chemistry 2]

[0022]

[0023] The present invention is based on the above-mentioned knowledge of the present inventors, and as a method for solving the above-mentioned problems, it is as follows. That is,

[0024] <1> A parasympathetic nerve activator, comprising a compound represented by the following structural formula (1).

[0025] [Chemistry 3]

[0026]

[0027] <2> The parasympathetic nerve activator according to <1> above, wherein the parasympathetic nerve is a parasympathetic nerve that controls at least one selected from the group consisting of a stomach, a pancreas, and an intestine.

[0028] <3> A parasympathetic nerve activating composition comprising the parasympathetic nerve activator according to <1> or <2> above.

[0029] Effects of the Invention

[0030] The parasympathetic nerve activator and the parasympathetic nerve activating composition of the present invention can solve the above-mentioned various problems of the prior art, achieve the above-mentioned objects, and provide a parasympathetic nerve activator and a parasympathetic nerve activating composition having excellent parasympathetic nerve activating effect and high safety. BRIEF DESCRIPTION OF THE DRAWINGS

[0031] Figure 1 Graph showing changes in nerve activity of the centrifugal branch of the gastric vagus (parasympathetic) nerve in Test Example 1.

[0032] Figure 2 This is a graph showing changes in the nerve activity of the centrifugal branch of the pancreatic vagus (parasympathetic) nerve in Test Example 1.

[0033] Figure 3 This is a graph showing changes in the neural activity of the centrifugal branch of the intestinal vagus (parasympathetic) nerve in Test Example 1. DETAILED DESCRIPTION

[0034] (Parasympathetic activator)

[0035] The parasympathetic nerve activator of the present invention contains the compound represented by the following structural formula (1) as an active ingredient, and further contains other ingredients as necessary.

[0036] [Chemistry 4]

[0037]

[0038] In the present specification, activation of parasympathetic nerves means increasing the activity of parasympathetic nerves compared to before administration of the parasympathetic nerve activator.

[0039] The parasympathetic nerve activator preferably activates parasympathetic nerves that control at least one selected from the group consisting of the stomach, pancreas, and intestines.

[0040] The compound represented by the structural formula (1) has a parasympathetic nerve activating effect and is useful as a parasympathetic nerve activator, which has not been known before and is a new finding of the present inventors.

[0041] <Compound represented by structural formula (1)>

[0042] The name of the compound represented by the following structural formula (1) is 3-(4-hydroxy-3-methoxyphenyl)propionic acid (English name: 3-(4-Hydroxy-3-methoxyphenyl)propionic acid) (hereinafter, sometimes referred to as "HMPA").

[0043] [Chemistry 5]

[0044]

[0045] The compound represented by the above structural formula (1) is a known compound, and a commercially available product may be used, or a compound extracted from a plant or the like may be used.

[0046] The content of the compound represented by the structural formula (1) in the parasympathetic nerve activator is not particularly limited and can be appropriately selected depending on the intended purpose.

[0047] The parasympathetic nerve activator may be formed only from the compound represented by the structural formula (1), and the compound represented by the structural formula (1) may be formulated.

[0048] <Other ingredients>

[0049] As the above-mentioned other components, there are no particular restrictions as long as the effects of the present invention are not impaired, and they can be appropriately selected according to the form of use of the above-mentioned parasympathetic nerve activator, and examples thereof include excipients, antiseptics, preservatives, enhancers, thickeners, emulsifiers, antioxidants, sweeteners, acidulants, seasonings, colorants, fragrances, whitening agents, moisturizers, oily components, ultraviolet absorbers, surfactants, alcohols, powder components, colorants, aqueous components, water, skin nutrients, etc. These may be used alone or in combination of two or more.

[0050] The content of the other components in the parasympathetic nerve activator is not particularly limited and can be appropriately selected depending on the intended purpose.

[0051] The parasympathetic nerve activator can be formulated into any dosage form such as powder, granule, tablet, liquid, etc. using pharmaceutically acceptable carriers such as dextrin and cyclodextrin and any other auxiliary agents according to conventional methods. In this case, as auxiliary agents, for example, excipients, binders, disintegrants, lubricants, stabilizers, flavoring agents, etc. can be used.

[0052] The parasympathetic nerve activator can be used in combination with other compositions (e.g., the parasympathetic nerve activating composition described below), or can be used as parenteral administration such as injections, drops, suppositories, ointments, eye drops, external liquids, patches, etc.

[0053] Furthermore, the parasympathetic nerve activator may contain other components having a parasympathetic nerve activating effect as an active ingredient together with the compound represented by the above structural formula (1), if necessary.

[0054] <Application>

[0055] The use of the parasympathetic nerve activator is not particularly limited and can be appropriately selected depending on the intended purpose. Examples thereof include a wide range of uses such as pharmaceuticals, quasi-drugs, and foods and beverages.

[0056] The parasympathetic nerve activator has an excellent parasympathetic nerve activating effect and is highly safe, and can be suitably used as an active ingredient of a parasympathetic nerve activating composition described below, for example.

[0057] The above-mentioned parasympathetic nerve activators are suitable for use in humans, but can be used in animals other than humans (eg, mice, rats, hamsters, dogs, cats, cows, pigs, monkeys, etc.) as long as their effects are exerted.

[0058] The above-mentioned parasympathetic nerve activator is preferably used for an individual whose parasympathetic nerve activity is lower than usual.

[0059] The administration method of the parasympathetic nerve activator is not particularly limited and can be appropriately selected depending on the intended purpose. Examples of the administration method include oral administration, parenteral administration, and external application.

[0060] The dosage form of the parasympathetic nerve activator is not particularly limited, and a known dosage form can be appropriately selected according to the purpose.

[0061] The method for producing the parasympathetic nerve activator in any dosage form is not particularly limited, and a known method can be appropriately selected.

[0062] The administration method, dosage, administration site, administration period, administration interval, etc. of the parasympathetic nerve activator are not particularly limited and can be appropriately selected depending on the purpose.

[0063] For example, examples of the dosage of the parasympathetic nerve activator for humans include 0.005 mg to 25 mg per day per 60 kg of body weight, calculated as the amount of the compound represented by the above structural formula (1).

[0064] In addition, as an example of the dosage of the above-mentioned parasympathetic nerve activator to humans for the purpose of enhancing the activity of the parasympathetic nerves that control the stomach, the daily dosage per 60 kg of body weight, converted into the amount of the compound represented by the above-mentioned structural formula (1), can be 0.5 mg to 25 mg.

[0065] In addition, as an example of the dosage of the above-mentioned parasympathetic nerve activator to humans for the purpose of enhancing the activity of the parasympathetic nerves that control the pancreas, the daily dosage per 60 kg of body weight, converted into the amount of the compound represented by the above-mentioned structural formula (1), is 0.005 mg to 2 mg.

[0066] In addition, as an example of the dosage of the above-mentioned parasympathetic nerve activator to humans for the purpose of enhancing the activity of the parasympathetic nerves that control the intestines (small intestine or large intestine), the daily dosage per 60 kg of body weight, converted into the amount of the compound represented by the above-mentioned structural formula (1), can be 0.005 mg to 2 mg.

[0067] Furthermore, the parasympathetic nerve activator of the present invention can be used as a reagent for research related to the action mechanism of parasympathetic nerve activation.

[0068] (Composition for activating parasympathetic nerves)

[0069] The parasympathetic nerve activating composition of the present invention contains the parasympathetic nerve activator of the present invention and further contains other components as necessary.

[0070] <Parasympathetic nerve activator>

[0071] The parasympathetic nerve activator is the parasympathetic nerve activator of the present invention.

[0072] The content of the parasympathetic nerve activator in the parasympathetic nerve activating composition is not particularly limited and can be appropriately adjusted according to the form of the parasympathetic nerve activating composition, and is preferably 0.0001% by mass to 20% by mass, more preferably 0.0001% by mass to 10% by mass, calculated as the amount of the compound represented by the structural formula (1). The parasympathetic nerve activating composition may consist solely of the parasympathetic nerve activator.

[0073] <Other ingredients>

[0074] The other components in the parasympathetic nerve activating composition are not particularly limited and can be appropriately selected according to the use form of the parasympathetic nerve activating composition. For example, the other components described in the above-mentioned parasympathetic nerve activating agent can be mentioned. These can be used alone or in combination of two or more.

[0075] The content of the other components in the parasympathetic nerve activating composition is not particularly limited and can be appropriately selected depending on the intended purpose.

[0076] <Form>

[0077] The form of the parasympathetic nerve activating composition is not particularly limited and can be appropriately selected depending on the intended purpose. Examples thereof include pharmaceuticals, quasi-drugs, and foods and beverages.

[0078] The parasympathetic nerve activating composition can be used daily, and can extremely effectively exert various physiological activities including parasympathetic nerve activating effects through the action of the compound represented by the structural formula (1) as an active ingredient.

[0079] The above-mentioned parasympathetic nerve activating composition is suitable for use in humans, but can be used in animals other than humans (eg, mice, rats, hamsters, dogs, cats, cows, pigs, monkeys, etc.) as long as their respective effects are exerted.

[0080] The above-mentioned parasympathetic nerve activating composition is preferably used for individuals whose parasympathetic nerve activity is lower than usual.

[0081] The administration method of the parasympathetic nerve activating composition is not particularly limited and can be appropriately selected depending on the intended purpose. Examples of the administration method include oral administration, parenteral administration, and external application, and oral administration is preferred.

[0082] As the composition used for above-mentioned oral use, for example, oral administration agent, diet can be enumerated.Here, so-called diet refers to that the possibility of causing harm to people's health is small, and in common social life, by oral or digestive tract casting and the food taken in, is not limited to the distinction of food, pharmaceuticals, quasi-drugs etc. on administrative division.Therefore, above-mentioned diet refers to the diet of the diet of the general food, health food (functional diet), health function food (specific health food, nutrition function food, functional labeling food), quasi-drugs, pharmaceuticals etc. that widely comprise oral intake.

[0083] There is no particular limitation on the type of the composition for oral administration, and it can be appropriately selected according to the purpose. For example, beverages such as tea beverages, refreshing drinks, carbonated drinks, nutritional drinks, fruit drinks, lactic acid drinks, alcoholic drinks, coffee drinks, and refreshing drinks containing coffee (including concentrated original solutions of these beverages and powders for adjustment); ice cream, smoothies, shaved ice and other ice creams; noodles such as soba noodles, udon noodles, vermicelli noodles, dumpling wrappers, shumai wrappers, Chinese noodles, and instant noodles; desserts such as sugar, candy, chewing gum, chocolate, hard candy, snacks, biscuits, jelly, jam, cream, baked snacks, and bread; marine products such as crabs, salmon, clams, tuna, sardines, shrimps, bonito, Spanish mackerel, whales, oysters, saury, squid, ark shells, scallops, abalone, sea urchins, fish roe, and shellfish; fish cakes, ham, sausages, etc. Processed foods from aquatic and livestock products; dairy products such as processed milk and fermented milk; oils and fats such as salad oil, tempura oil, margarine, mayonnaise, puff pastry, fresh cream, and sauces, and foods processed with oils and fats; seasonings such as sauces and dressings; steamed and cooked foods such as curry, stew, chicken and egg rice, porridge, porridge with stew, Chinese rice, fried pork cutlet rice, tempura rice, eel rice, beef rice, oden, mapo tofu, beef rice, meat sauce, egg soup, omelette rice, dumplings, steamed buns, hamburgers, and meatballs; home-cooked dishes such as salads and pickles; various forms of health, beauty, and nutritional supplements; pharmaceuticals and quasi-pharmaceuticals such as tablets, powders, capsules, granules, extracts, syrups, oral liquids, lozenges, and gargles; oral fresheners and toothpastes used in the mouth such as mouth fresheners and bad breath preventers.

[0084] The method for producing the parasympathetic nerve activating composition is not particularly limited, and can be appropriately selected according to the form of use of the parasympathetic nerve activating composition and the like.

[0085] The amount of the parasympathetic nerve activating composition used, the site of use, the period of use, the interval of use, etc. are not particularly limited and can be appropriately selected depending on the purpose.

[0086] For example, the dosage of the parasympathetic nerve activating composition for human use is 0.005 mg to 25 mg per day per 60 kg of body weight, calculated as the amount of the compound represented by the structural formula (1).

[0087] In addition, as an example of the dosage of the above-mentioned parasympathetic nerve activating composition for human use when the purpose is to enhance the activity of the parasympathetic nerves that control the stomach, the daily dosage per 60 kg of body weight, converted into the amount of the compound represented by the above-mentioned structural formula (1), can be 0.5 mg to 25 mg.

[0088] In addition, as an example of the dosage of the above-mentioned parasympathetic nerve activating composition for human use when the purpose is to enhance the activity of the parasympathetic nerves that control the pancreas, the daily dosage per 60 kg of body weight, converted into the amount of the compound represented by the above-mentioned structural formula (1), can be 0.005 mg to 2 mg.

[0089] In addition, as an example of the dosage of the above-mentioned parasympathetic nerve activating composition for human use when the purpose is to enhance the activity of the parasympathetic nerves that control the intestines (small intestine or large intestine), the daily dosage per 60 kg of body weight, converted into the amount of the compound represented by the above-mentioned structural formula (1), can be 0.005 mg to 2 mg.

[0090] As described above, the parasympathetic nerve activator and the parasympathetic nerve activating composition of the present invention have excellent parasympathetic nerve activating action.

[0091] Therefore, the present invention also relates to a method for activating parasympathetic nerves, characterized in that at least one selected from the group consisting of the above-mentioned parasympathetic nerve activating agent and parasympathetic nerve activating composition is administered to an individual.

[0092] Furthermore, if the activity of the parasympathetic nerves that control the stomach is activated, gastrointestinal function is promoted, gastric acid secretion, gastric motility, and digestion and absorption functions are improved.

[0093] When the activity of the parasympathetic nerves controlling the pancreas increases, the release of digestive enzymes from the exocrine glands into the intestines is promoted, thereby promoting digestive function. In addition, the secretion of insulin from the β cells of the pancreatic islets, which are endocrine glands, is promoted, thereby having an anti-diabetic effect of lowering blood sugar levels.

[0094] If the activity of the parasympathetic nerves that control the intestine increases, the digestion and absorption capabilities of the intestine are improved, and the peristaltic movement of the intestine is promoted, thereby promoting bowel movements.

[0095] Therefore, the present invention also relates to a digestion promoter, a blood sugar lowering agent, or a peristaltic motility promoter comprising the compound represented by the above structural formula (1). In addition, it also relates to a digestion promoting composition comprising the above digestion promoter, a blood sugar lowering composition comprising the above blood sugar lowering agent, or a peristaltic motility promoting composition comprising the above peristaltic motility promoter. Further, it also relates to a digestion promoting method, characterized in that at least one selected from the group consisting of the above digestion promoter and the digestion promoting composition is administered to an individual; a blood sugar lowering method, characterized in that at least one selected from the group consisting of the above blood sugar lowering agent and the blood sugar lowering composition is administered to an individual; or a peristaltic motility promoting method, characterized in that at least one selected from the group consisting of the above peristaltic motility promoter and the peristaltic motility promoting composition is administered to an individual.

[0096] Example

[0097] Hereinafter, test examples and formulation examples of the present invention will be described, but the present invention is not limited to these test examples and formulation examples.

[0098] (Test Example 1)

[0099] The effect of intragastric administration of the compound represented by the above structural formula (1) on the activity of the parasympathetic nerves that control the stomach, pancreas, or intestines was tested as follows.

[0100] <Measurement>

[0101] The experiment was conducted in a 24°C constant temperature animal room with a light-dark cycle of 12 hours (lights on until 8:00-20:00), using Wistar male rats (about 9 weeks old) weighing about 300 g. After fasting for 3 hours on the day of the experiment, the rats were anesthetized with urethane, and a cannula for intragastric administration was inserted. Then, the centrifugal branches of the parasympathetic nerves (vagus nerves) that control the stomach, pancreas, or intestines (small intestine and large intestine) were suspended with silver electrodes, and the electrical activities of each were measured.

[0102] When their measured values ​​were stable (around 13:00), an aqueous solution of the compound represented by the above structural formula (1) (manufactured by Tokyo Chemical Industry) was administered intragastrically at a dosage of 0.015 mg / 0.5 mL / 300 g body weight, 0.0015 mg / 0.5 mL / 300 g body weight, or 0.00015 mg / 0.5 mL / 300 g body weight using a cannula, and the changes in the nerve activity of the centrifugal branches of these parasympathetic nerves were electrophysiologically measured for 60 minutes. In addition, as a control, water as a solvent was administered intragastricly at a dosage of 0.5 mL / 300 g body weight using a cannula, and the changes in the nerve activity of the centrifugal branches of these parasympathetic nerves were electrophysiologically measured for 60 minutes.

[0103] From the start of surgery until the end of measurement, a tube was inserted into the trachea to secure the airway, and the body temperature (rat rectal temperature) was maintained at 37.0±0.5°C in a warming device.

[0104] The data of neural activity were analyzed as the average value of the firing frequency (pulse / 5s) for 5 seconds every 5 minutes, and expressed as a percentage with the average value (0 score) for 5 minutes before the start of stimulation being 100%.

[0105] <Results>

[0106] -Stomach-

[0107] The results are shown in Table 1. Changes in gastric vagal nerve activity (GVNA) in the centrifugal branch of the gastric vagal (parasympathetic) nerve when an aqueous solution containing 0.015 mg of the compound represented by the above structural formula (1) was administered at a dosage of 0.5 mL / 300 g body weight or water as a solvent was administered at a dosage of 0.5 mL / 300 g body weight. The results are shown in Table 1. Figure 1 .

[0108] Figure 1 As shown, an aqueous solution containing 0.015 mg of the compound represented by the above structural formula (1) was administered at a dose of 0.5 mL / 300 g body weight to the group ( Figure 1 In the group ( Figure 1 From this result, it can be seen that the compound represented by the above structural formula (1) has the effect of activating the activity of the parasympathetic nerves that control the stomach.

[0109] If the activity of the parasympathetic nerves that control the stomach increases, gastrointestinal function is promoted, gastric acid secretion, gastric motility, and digestion and absorption functions are improved.

[0110] - Pancreas -

[0111] The results are shown in Table 1. Changes in the pancreatic vagal nerve activity (PVNA) of the centrifugal branch of the parasympathetic nerve when 0.0015 mg or 0.00015 mg of an aqueous solution containing the compound represented by the above structural formula (1) at a dosage of 0.5 mL / 300 g body weight or water as a solvent at a dosage of 0.5 mL / 300 g body weight were intragastrically administered. The results are shown as percentages of the average value (0 score) of the nerve activity in the first 5 minutes before intragastrically administering the compound represented by the above structural formula (1) as 100%. Figure 2 .

[0112] Figure 2 As shown, an aqueous solution containing 0.0015 mg of the compound represented by the above structural formula (1) was administered at a dose of 0.5 mL / 300 g body weight to the group ( Figure 2 ) and a group to which an aqueous solution containing 0.00015 mg of the compound represented by the above structural formula (1) was administered at a dose of 0.5 mL / 300 g body weight ( Figure 2 In the group ( Figure 2The results show that the compound represented by the structural formula (1) has an effect of activating the activity of the parasympathetic nerves that control the pancreas.

[0113] When the activity of the parasympathetic nerves that control the pancreas increases, the release of digestive enzymes from the exocrine glands into the intestines is promoted to promote digestive function, and insulin secretion from the β cells of the pancreatic islets, which are endocrine glands, is promoted to have an anti-diabetic effect of lowering blood sugar levels.

[0114] -intestinal-

[0115] The results are shown in Table 1. Changes in intestinal vagal nerve activity (IVNA) when 0.0015 mg or 0.00015 mg of an aqueous solution containing the compound represented by the above structural formula (1) at a dosage of 0.5 mL / 300 g body weight or water as a solvent at a dosage of 0.5 mL / 300 g body weight were intragastrically administered. The results are shown as percentages of the average value (0 score) of the nerve activity in the first 5 minutes before intragastrically administering the compound represented by the above structural formula (1) at a dosage of 0.5 mL / 300 g body weight. Figure 3 .

[0116] Figure 3 As shown, an aqueous solution containing 0.0015 mg of the compound represented by the above structural formula (1) was administered at a dose of 0.5 mL / 300 g body weight to the group ( Figure 3 ) and a group to which an aqueous solution containing 0.00015 mg of the compound represented by the above structural formula (1) was administered at a dose of 0.5 mL / 300 g body weight ( Figure 3 In the group ( Figure 2 The IVNA value is higher than that of the compound represented by the structural formula (1). This result shows that the compound represented by the structural formula (1) has the effect of activating the activity of the parasympathetic nerves that control the intestines (small intestine and large intestine).

[0117] If the activity of the parasympathetic nerves that control the intestines increases, the digestion and absorption capabilities of the intestines are improved, and the peristaltic movement of the intestines is promoted, thereby promoting bowel movements.

[0118] (Matching Example 1)

[0119] Tablets having the following composition were produced by a conventional method.

[0120]

[0121] (Matching Example 2)

[0122] An oral liquid preparation having the following composition was produced by a conventional method.

[0123] <Composition in 1 ampoule (1 bottle 100mL)>

[0124]

[0125]

[0126] (Matching Example 3)

[0127] By a conventional method, a coffee beverage having the following composition was produced.

[0128]

[0129] (Matching Example 4)

[0130] A capsule having the following composition was produced by a conventional method. In addition, a No. 1 hard gelatin capsule was used as the capsule.

[0131] <Composition of 1 capsule (200 mg per capsule)>

[0132]

[0133] This application claims the priority based on Japanese Patent Application No. 2022-079699 filed on May 13, 2022, and all contents of Japanese Patent Application No. 2022-079699 are incorporated herein by reference.

Claims

1. A parasympathetic nerve activator, characterized in that Contains a compound represented by the following structural formula (1), [Chemistry 1] 2. The parasympathetic nerve activator according to claim 1, The parasympathetic nerve is a parasympathetic nerve that controls at least one selected from the group consisting of a stomach, a pancreas, and an intestine.

3. A parasympathetic nerve activating composition, characterized in that: The invention comprises the parasympathetic nerve activator according to claim 1 or 2.

Images